Newcastle Gateshead CCG goes live with FDB OptimiseRx™ to drive high-quality and cost-effective prescribing
NHS Newcastle Gateshead CCG has become the latest CCG to go live with FDB OptimiseRx this week.
FDB OptimiseRx will be tailored to reflect the guidance that is approved by the North of Tyne & Gateshead Area Prescribing Committee – the organisation responsible for clinical decision making and advice in relation to prescribing and medicines optimisation in the North East.
FDB is supporting the CCG by running GP Practice engagement sessions to train and support primary care teams, and to raise awareness of the benefits. Benefits of FDB OptimiseRx to Newcastle Gateshead CCG will include:
- Patient-specific guidance on when it is appropriate for patients to self-care
- Encouraging safe, effective and economical prescribing
- Closer adherence to North of Tyne & Gateshead Area Prescribing Committee Joint Formulary
- Enhanced collaboration and partnership with the medicines teams across the STP
- Supporting the QIPP target
Dr Neil Morris, Medical Director at NHS Newcastle Gateshead CCG said: “We are pleased to be enabling FDB OptimiseRx in our GP Practices this week. It is the first tool of its kind to consider the full patient history, observations, measurements, polypharmacy issues and multiple morbidities ensuring only the most appropriate recommendations are provided to support our prescribers to make the best possible prescribing decisions for our patients.”
He continues: “The patient-specific nature of the solution will mean that prescribers will have confidence that they are making a medication choice that is in line with the latest national clinical evidence and our local guidelines. It’s going to support our strategy of driving a consistent application of best practice, formulary compliance and cost benefits across the Newcastle and Gateshead area.”
All CCGs within the Northumberland, Tyne and Wear and North Durham Sustainability and Transformation Partnership (STP) are now using FDB OptimiseRx to drive a positive improvement to GP prescribing, positively impacting more than 1.7 million patients.